Generation Bio Co.

As of November 9, 2023, Generation Bio Co. is rated as risky due to significant losses and poor performance metrics, with a negative P/E ratio of -0.6048, indicating overvaluation compared to peers and a year-to-date stock return of -43.58%, significantly underperforming the S&P 500's 12.22% return.

As of November 9, 2023, Generation Bio Co. is rated "risky" and considered overvalued, with key financial metrics indicating a negative return on equity of -86.41% and a year-to-date stock performance of -66.05%, significantly underperforming the S&P 500.

As of April 28, 2025, the market trend is mildly bearish due to bearish signals from daily moving averages and Bollinger Bands, despite some mildly bullish indicators from the weekly MACD and KST.

As of March 2022, the management team of Generation Bio Co. includes Jason Rhodes (Independent Chairman), Dr. Cameron McDonough (President and CEO), and four Independent Directors: Gustav Christensen, Dr. Jeffrey Jonas, Dr. Donald Nicholson, and Dr. Anthony Quinn.

Generation Bio Co. is a genetic medicines company focused on non-viral gene therapies for rare and prevalent diseases, with a market cap of $25.61 million and a quarterly net sales of $9 million. As of March 2025, the company reported a net profit loss of $15 million.

As of Jun 18, Generation Bio Co. has a market capitalization of 25.61 million, with net sales of 24.55 million and a net profit of -71.92 million over the last four quarters. Shareholder's funds are 86.20 million, and total assets are 231.20 million as of Dec 24.